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Background: Antigen-specific immunotherapy (SIT) has been widely practiced in treating allergic diseases such
as asthma. However, this therapy may induce a series of allergic adverse events during treatment. Peptide
immunotherapy (PIT) was explored to overcome these disadvantages. We confirmed that multiple antigen peptides
(MAPs) do not cause autoimmune responses, which led to the presumption that MAPs intervention could alleviate
allergic airway inflammation without inducing adverse effects.
Results: In this study, synthesized OVA323-339MAP octamers were subcutaneously injected into ovalbumin (OVA)-
sensitized and -challenged Balb/c mice to observe its effect on allergic airway inflammation, Th2 immune response,
and immune regulating function. It was confirmed that OVA sensitization and challenge led to significant
peritracheal inflammatory, cell infiltration, and intensive Th2 response. Treatment of OVA323-339MAP octomers in the
airway inflammation mice model increased CD4+CD25+Foxp3+ T regulatory (Treg) cells and their regulatory
function in peripheral blood, mediastinal draining lymph nodes, and the spleen. Furthermore, OVA323-339MAP
increased IL-10 levels in bronchial alveolar lavage fluid (BALF); up-regulated the expression of IL-10,
membrane-bound TGF-β1, as well as Foxp3 in lung tissues; and up-regulated programmed death-1 (PD-1) and
cytotoxic T lymphocyte associated antigen 4 (CTLA-4) on the surface of Treg cells. These results were further
correlated with the decreased OVA specific immunoglobulin E (sIgE) level and the infiltration of inflammatory cells
such as eosinophils and lymphocytes in BALF. However, OVA323-339 peptide monomers did not show any of the
mentioned effects in the same animal model.
Conclusions: Our study indicates that OVA323-339MAP had significant therapeutic effects on mice allergic airway
inflammation by regulating the balance of Th1/Th2 response through Treg cells in vivo.
Keywords: Allergic airway inflammation, Specific immunotherapy, Multiple antigen peptideBackground
Bronchial asthma, one of the most common chronic in-
flammatory diseases, has complex pathogenic mechan-
isms. As an allergic disease, it is mediated mainly by Th2
immune responses, and is affected by genetic as well as
environmental factors. Many approaches for treating this
disease are palliative rather than disease modifying. In
the past century, antigen-specific immunotherapy (SIT)* Correspondence: xzw63@hotmail.com
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reproduction in any medium, provided the orhas been widely practiced in treating allergic diseases,
and has been a form of disease-modifying treatment,
which has been demonstrated to be clinically efficacious
in asthma [1,2]. However, the SIT desensitizers com-
monly used presently are whole allergen preparations
that have the potential to induce a series of adverse
allergic events that can, at times be fatal [3]. On this
basis, many approaches that can reduce the aller-
genicity of immunotherapy preparations and maintain
their immunogenicity are under development. One of
these approaches is peptide immunotherapy (PIT),
which utilizes synthesized short peptides containing
major T cell epitopes of the allergen. This approach
could present allergen-derived T cell epitopes whileThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells or basophils. Synthesized short peptides contai-
ning major T cell epitopes of cat allergen Fel d1, dust
mite allergen Der p2, birch pollen allergen Bet v1
and bee venom allergen Api m1 have been demonstrated
to be efficacious in experimental animal models in recent
years [4-7].
Clinical studies have also shown that in patients alle-
rgic to cats, rhinitis symptom scores, asthma symptom
scores, and lung function were all improved markedly
after peptide treatment [8-14]. However, some conflic-
ting results were also reported. Janssen et al. [15] found
that OVA323-339 peptides containing major T cell epi-
topes of ovalbumin (OVA) proteins do not mitigate the
effects of airway inflammation, but conversely, aggravate
disease in OVA-induced asthmatic mice. The same re-
sult has been observed in encephalomyelitis (EAE) mice
model. Wegman et al.[16] found that PLP139-151 peptide
(proteolipid protein) monomers had no effect in impro-
ving disease, while synthesized PLP139-151 multiple anti-
gen peptide (MAP) octamers successfully inhibited the
occurrence of EAE induced by encephalitis pathogenic
protein, thus demonstrating that peptide monomers pro-
cessing can alter their immunological characteristics.
MAPs are dendriform peptides, which can be tetramers
or more typically, octamers. Each peptide monomer is in-
dependently and covalently linked to a branched central
lysine matrix. MAPs can induce high levels of immune
response and have been used in vaccine development for a
variety of infectious diseases [17,18]. In addition, MAPs
can also enhance the peptide-specific T cell response and
play a role in the protective immune response [19-22].
Also, Wegman et al.[16] further expanded the scope of
MAPs application in studies of autoimmune diseases.
There have been no reports of studies concerning the
treatment of allergic airway inflammation using MAPs.
Therefore, in the present study, eight OVA323-339 short
peptides were integrated on a lysine core matrix to
constitute OVA323-339MAP octamers, which were then
subcutaneously injected into OVA-induced allergic
airway inflammation mice. The inhibitory effect of
OVA323-339MAP on airway inflammation and Th2 immune
response were observed and compared with OVA323-339
monomers.
Based on the current theories, T regulatory (Treg)
cells proliferation is crucial in maintaining homeos-
tasis. However, existing research on the role of Treg
cells in PIT treatment remain controversial [23,24].
In our preliminary study, we found that Treg cells
played an important immunoregulatory role in the devel-
opment and progression of airway inflammation in mice
[25,26]. Thus, the changes of Treg cells after OVA323-339
MAP octamer treatment were further explored in this
study.Results
OVA323-339MAP intervention attenuates OVA-induced
airway inflammation
Recently, MAPs have been shown to alleviate the seve-
rity and block the progress of EAE [16]. This finding
emphasizes the potential of MAPs intervention as an ef-
fective immunotherapy to treat antigen-specific allergic
diseases. Thus, to examine the impact of MAPs on aller-
gic lung disease, we sensitized Balb/c mice with OVA
emulsified in Al(OH)3 and induced airway inflammation
by intranasal administration of the antigen. As illustrated
in Figures 1 and 2 A, OVA priming and activation led to
a high inflammation score associated with marked peri-
bronchial leukocyte infiltration, edema, and epithelial
damage. Systemic administration of regular OVA323-339
peptide before local antigen activation did not alter the
severity of the airway inflammation and tissue injury,
whereas treatment with OVA323-339MAP substantially
reduced the inflammatory response in a dose-dependent
manner. In addition to the histological evaluation, we
assessed airway inflammation by examining total cell
counts and eosinophil, neutrophil, lymphocytes and
macrophages counts in bronchial alveolar lavage fluid
(BALF) of these mice. Compared to the normal control
group, OVA sensitization and challenge induced a signifi-
cant increase of total cells, eosinophils, neutrophils, lym-
phocytes and macrophages counts, OVA323-339 peptide
monomers intervention mildly reduced the total cell
count and EOS number. However, a significant decrease
in total cell as well as EOS and LYM infiltrates was
observed in OVA323-339MAP treated mice (Table 1).
Antigen specific immunoglobulin E (sIgE) plays an
important role in allergic cell degranulation and hy-
perresponsiveness. Therefore, we tested whether MAPs
intervention altered immunoglobulin production and
switching. As shown in Figure 2 B, no OVA-sIgE was
detected in the serum of control animals, whereas OVA
challenge led to a robust production of IgE that specific-
ally recognizes OVA. Conversely, OVA323-339MAP treat-
ment significantly suppressed the level of OVA-sIgE.
Interestingly, the mice administered with OVA323-339MAP
had a substantial elevation of OVA-specific immunoglobu-
lin G1 (sIgG1) which is the indicator for the success of im-
munotherapy, compared to the control and OVA323-339
peptide monomers treated groups (Figure 2 C). This data
suggest that OVA323-339MAP intervention may mitigate
the antigen-specific allergic process and response.
Based on the above results, we further explored how
the OVA323-339MAP mitigates the airway allergic airway.
OVA323-339MAP intervention alters the OVA-induced Th2
response
It is well documented that OVA-induced airway inflam-
mation in Balb/c mice is mainly mediated by a Th2
Figure 1 Impact of OVA323-339 and OVA323-339MAP intervention on airway inflammation in mice. After OVA sensitization and challenge,
typical airway inflammation was observed in Balb/c mice. The airway inflammation was not significantly alleviated by subcutaneous injection of
200 μg of OVA323-339 peptide monomers. However, OVA323-339MAP, containing the equivalent weight of peptides, significantly reduced
peritracheal inflammatory cells infiltration and this effect was dose-dependent. Data represent one of three independent experiments.
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can attenuate allergic airway inflammation, we asked if
OVA323-339MAP treatment alters the OVA-induced Th2
response in the host. To this end, we measured the ex-
pression of Th1/Th2-related cytokines (IFN-γ, IL-4, IL-5
and IL-13) and the ratio of IFN-γ/IL-4 in the BALF of
these mice. The levels of IL-4, IL-5 and IL-13 were
significantly elevated in mice challenged with OVA
(Figure 3 A, D, E), while the ratio of IFN-γ/IL-4 decrea-
sed significantly (Figure 3 C). However, OVA323-339MAP
intervention reduced local Th2 cytokines production
and increased the level of IFN-γ and the ratio of IFN-γ/IL-4 (Figure 3 A ~ E). Furthermore, in order to deter-
mine if OVA323-339MAP treatment influences antigen re-
call response in mice sensitized with OVA, splenocytes
from control and OVA-challenged mice with or without
OVA323-339MAP intervention were harvested. The IL-4
and IFN-γ positive populations were analyzed by flow
cytometry (FCM) in CD4+ T cells and the amount of IL-4,
IL-5, IL-13 and IFN-γ in the cell culture media were
quantified by ELISA. When the lymphocytes were re-
stimulated with OVA in vitro, CD4+ T cells from
OVA-challenged mice exhibited a significantly higher IL-4
production than the control group. In vivo treatment with
Figure 2 Peribronchila inflammation score and immunoglobulin levels in serum. The peribronchial inflammation score and OVA-sIgE levels
in OVA group and OVA323-339 group were significantly increased, but they were significantly decreased accompanied by increased OVA-sIgG1
after OVA323-339MAP treatment (* compared with the control group, P< 0.05; # compared with the OVA323-339 group, P< 0.05). Data represent one
of three independent experiments.
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tion in response to OVA re-stimulation (Figure 4 A, G).
Likewise, ELISA demonstrated that splenocytes from
OVA-challenged mice exhibited a significantly higher
IL-4, IL-5 and IL-13 response to antigen re-stimulation,
while this antigen recall response was diminished in
OVA323-339MAP-treated mice (Figure 4 B, E, F). Interes-
tingly, OVA323-339MAP intervention caused more IFN-γ
products while the levels of IFN-γ between the control
and airway inflammation groups were biologically in-
significant (Figure 4 C). These results suggest that
OVA323-339MAP may alter Th2 response in this allergic
airway model.
OVA323-339MAP intervention increased the populations
of CD4+CD25+Foxp3+ Treg cells, up-regulated the pro-
duction of IL-10, membrane-bound TGF-β1 and Foxp3 in
the lung, as well as the surface expression of PD-1 and
CTLA-4
In light of these findings, we evaluated whether
OVA323-339MAP induces peripheral tolerance as a part of
a potential mechanism for mitigating OVA-induced air-
way inflammation. Treg cells regulate the functions of
other CD4+CD25- effector cells and play an important role
in balancing Th1/Th2 cell differentiation. Therefore, we
observed the alteration of Treg cells. CD4+CD25+Foxp3+
Treg cells in peripheral blood, mediastinal draining lymphTable 1 Total Cells and Differential Cells Counts in BALF (×10
Total cells Eosinophils
Control 8.91 ± 1.17 0.00 ± 0.00
OVA 74.64 ± 12.60 * 9.08 ± 2.20 *
OVA+OVA323-339 63.64 ± 8.07 # 4.58 ± 0.86 #
OVA+MAPs 43.32 ± 5.64 } 1.02 ± 0.16 }
*P< 0.05 Compared with Control group.
#P< 0.05 Compared with OVA group.
}P< 0.05 Compared with OVA + OVA323-339 group.nodes, and spleen were measured by FCM. In vivo OVA
challenge decreased the level of Treg cells in the mice.
However, OVA323-339MAP increased the population of
local and peripheral CD4+CD25+Foxp3+ Treg cells ap-
proximately 0.5-1.0 fold (Figure 5). In addition, we further
detected the Foxp3 transcription expression in the lung to
observed Treg cells in inflamed local tissue. The result
showed that Foxp3 expression in the lung was augmented
by MAPs intervention (Figure 3 J).
CD4+CD25+Foxp3+ Treg cells exert their regulatory
effect on immune effector cells by both direct contact
and indirect suppression. The indirect suppression is
mediated by anti-inflammatory cytokines including IL-
10 and transforming growth factor (TGF)-β1. Thus, we
measured IL-10 and TGF-β1 levels in BALF and their
expression in lung tissue. As shown in Figure 3 F and I,
OVA challenge significantly decreased the level of IL-10
in BALF and lung tissue, but OVA323-339MAP interven-
tion increased its concentration. Although the level of
TGF-β1 in BALF was not affected by MAPs (Figure 3
G), the transcription of TGF-β1 in lung was significantly
decreased in OVA challenge mice when compared to
control mice. However, it is important to note that
OVA323-339MAP intervention could reverse this change
which is consistent with the results shown in our pre-
vious publication (Figure 3 H) [25].4)
Neutrophils Lymphocytes Macrophages
0.05 ± 0.00 0.19 ± 0.01 8.37 ± 1.57
2.12 ± 0.52 * 4.51 ± 1.43 * 58.41 ± 10.05 *
1.03 ± 0.15 3.06 ± 0.52 55.59 ± 9.91
0.92 ± 0.16 0.86 ± 0.11 } 40.24 ± 6.29
Figure 3 The levels of cytokines in BALF and in the lung. OVA323-339MAP treatment could reverse OVA-induced response, reducing the IL-4,
IL-5, and IL-13 levels, increasing the level of IFN-γ and IL-10 and regulating the ratio of IFN-γ/IL-4. For the level of TGF-β1 in BALF, there were no
markedly differences in each group, but the TGF-β1 mRNA expression was enhanced significantly after OVA323-339MAP intervention. In addition,
the expression levels of IL-10 and Foxp3 in the lung tissue were higher in MAPs group than that of control and OVA groups. (* compared with
the control group, P< 0.05; # with the OVA group, P< 0.05). Data represent one of three independent experiments.
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function, co-stimulatory molecules such as programmed
death (PD)-1 and cytotoxic T lymphocyte associated
antigen (CTLA)-4 contribute to the regulatory function
of Treg cells. Therefore, we investigated the expression
of PD-1 and CTLA-4 on the surface of Treg cells by
FCM. Interestingly, compared to the control mice, OVAchallenge elevated the expression of PD-1 mildly,
however, the ratio of PD-1+ Treg cells increased sig-
nificantly after treatment with OVA323-339MAP in
blood, mediastinal draining lymph nodes, and spleen.
The similar alteration of CTLA-4 expression on the
surface of Treg cells was observed in same tissues
(Figure 6).
Figure 4 Th2 cells differentiation in spleen. Splenocytes were co-cultured with OVA (1 mg/ml) in vitro for the examination of Th2 cells
differentiation. OVA323-339MAP intervention could significantly reduce the ratio of CD4
+IL-4+ T cells compared with the OVA group (gating on
CD4+ T cell populations). ELISA detection of the cytokines in supernatant showed that IL-4, IL-5, and IL-13 levels were significantly increased in
the OVA group compared with the control group, but OVA323-339MAP intervention could significantly suppress their secretion and enhance the
expression of IFN-γ, then the ratio of IFN-γ/IL-4 was increased. (* compared with the control group, P< 0.05; # compared with the OVA group,
P< 0.05). Data represent one of three independent experiments.
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mice, we isolated CD4+CD25+ Treg cells from OVA-
challenged mice, with or without OVA323-339MAP
treatment. The Treg cells were co-cultured with effec-
tor CD4+ lymphocytes and CD11c+ antigen presenting
cells (APCs) from the normal untreated mice. Five
days later, effector T cells proliferation in response to
in vitro OVA stimulation was assessed by FCM. The
results showed that effector T cells underwent six
proliferation cycles when they were cultured with
Treg cells from OVA-challenged mice, the same as
that of effector T cells without Treg. Despite OVA
challenge, the Treg cells from the mice treated with
OVA323-339MAP displayed a regulatory function, as
evidenced by reduced effector T cell proliferation
cycles (Figure 7).Discussion
The OVA323-339 peptides used in this experiment con-
tained major T cell epitopes, representing major peptides
that could be presented to Th cells through MHC class II
molecules after APCs processing of OVA proteins. Struc-
tural analysis has confirmed that OVA323-339 peptides con-
tain multiple loci that can be combined with MHC class
II molecules and TCRs to form an immune sandwich
complex and induce an immune response [27]. It has also
been demonstrated that after OVA323-339 peptide chal-
lenge, 82% of OVA-sensitized mice developed immediate
hypersensitivity. In addition, OVA and OVA323-339 pep-
tides are equivalent in increasing mice airway reaction
during challenge test [28]. Thus, OVA323-339 peptides have
been considered for use in PIT in OVA-induced asthma
in mice. However, Janssen et al.[15] found that after using
Figure 5 FCM detection of CD4+CD25+Foxp3+ Treg cells in peripheral blood, mediastinal draining lymph nodes, and spleen of mice. In
vivo OVA challenge could decrease the level of Treg cells in the mice. However, the levels of local and peripheral CD4+CD25+Foxp3+ Treg cells
was about 0.5-1.0-fold increase after OVA323-339MAP treatment (gating on CD4
+ T cell populations, * compared with the control group, P<0.05; #
compared with the OVA group, P<0.05). Data represent one of three independent experiments.
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inflammation was alleviated nor were OVA-sIgE levels
and Th2 immune responses suppressed, which are the
opposite of the expected results. In our study, similar
results were found using OVA323-339 peptide monomers,
while after OVA323-339MAP intervention, airway inflam-
mation in mice was significantly alleviated and EOS infil-
tration decreased markedly. These results suggest thatOVA323-339MAP, instead of OVA323-339 peptide monomers
have a significant antagonizing effect on airway inflamma-
tion. The previous reports confirmed that the branching
lysine core is an immunologically silent dendrimeric struc-
ture [29], therefore, the effects of MAPs were not caused
by the lysine core.
In addition, the effect of OVA323-339MAP on airway
inflammation was dose-dependent. In clinical study, it
Figure 6 (See legend on next page.)
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Figure 6 FCM detection of PD-1 and CTLA-4 on the surface of CD4+CD25+Foxp3+ Treg cells in peripheral blood, mediastinal draining
lymph nodes, and spleen of mice. To evaluate whether Treg cells in this study could play their role by contact inhibition, the surface
expression of two major negative co-stimulatory molecules were detected by FCM. Freshly isolated cells from blood, mediastinal draining lymph
nodes and spleen were stained with fluorescently antibodies for CD4, CD25, Foxp3 and PD-1 or CTLA-4. The results showed a significantly higher
levels of PD-1 and CTLA-4 on the surface of Treg cells in MAPs treated mice than in control mice and OVA treated mice (gating on CD4+CD25+
cells).
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T cell unresponsiveness and also trigger apoptosis of
Th2 cells in allergen stimulated periphery blood mono-
nuclear cell (PBMC) from patients receiving SIT treate-
ment [30-33]. Further analysis found that after MAPs
intervention, the level of OVA-sIgE in periphery blood
was significantly reduced, while OVA-sIgG1 level was
significantly increased. These results indicated that
OVA323-339MAP intervention could affect the class-switch
of OVA-specific immunoglobulin. Clinical trials have
shown that allergen-sIgE level gradually decrease in aller-
gic patients as a successful treatment proceeds, while the
levels of sIgGs, especially IgG1 and IgG4 gradually increase
[34,35]. Therefore, immunoglobulin class-switch is con-
sidered to be one of the important indicators reflecting
the success of immunotherapy [36,37]. These results also
showed that OVA323-339MAP could alter the immuno-
logical characteristics of monomer peptides after poly-
merization and possessed the opposite effect to peptide
monomers. Wegman’s study[16] also supported this
conclusion. They found that PLP139-151MAP instead of
PLP139-151 peptide monomer applied for intervention in
encephalitogenic proteolipid protein PLP139-151 peptide-
induced EAE mice could prevent antigen-specific T
cells trafficking into the brain, thereby inhibiting in-
flammation. Our study showed that OVA323-339MAP
suppressed Th2 immune response; reduced IL-4, IL-5,
and IL-13 levels in either BALF or splenocyte culture
supernatant significantly as well as the ratio of Th2Figure 7 FCM detection of the inhibitory effect of Treg cells on Teff p
challenged with or without intervention mice were isolated using immuno
CD11c+ APC from normal mice for 5 days with OVA (1 mg/ml) stimulation.
assessed by FCM. The results showed that the proliferation cycles of Teff ce
that in the OVA group and Teff without Treg cells group (six cycles). Data rcells in spleen concurrently. Up-regulated ratio of IFN-γ/
IL-4 reflected that MAPs could affect the Th1/Th2 im-
mune balance by inhibiting Th2 cell differentiation and
Th2 immune responses.
It is well documented that Treg cells are essential for
regulating immune effector cells, balancing Th1/Th2
response. They are a marker of tolerance induction in
controlling autoimmune diseases and maintaining im-
mune tolerance. CD4+CD25+ cells are a well characterized
Treg population and possess potent immunosup-
pressive functions. Thus, we examined the quantity
of Treg cells in our model. The results showed that
OVA323-339MAP intervention significantly increased the
ratio of CD4+CD25+Foxp3+ Treg cells in peripheral blood,
mediastinal draining lymph nodes, and spleen of mice.
Transcription factor Foxp3 is not only highly expressed in
Treg cells, but also correlated with Treg activation. Thus,
we further detected the level of transcription factor Foxp3
in the lung tissue by real-time PCR to evaluate the effect
of Treg cells in lung tissue. The results indicated that the
expression of Foxp3 is augmented significantly in MAPs
treated mice. IL-10 is an anti-inflammatory cytokine pro-
duced by Treg cells. CD4+CD25+Foxp3+ Treg cells exert
their anti-inflammatory effect through IL-10, which
also promotes the conversion of CD4+CD25- Treg cells
to CD4+CD25+ Treg cells. IL-10 suppresses T cells by
blocking CD2, CD28, and inducible costimulatory mole-
cule (ICOS) signals through a rapid signal transduction
cascade, leading to T cell tolerance. IL-10 can also down-roliferation. CD4+CD25+ T cells from normal mice and OVA-
magnetic beads, then co-cultured with effector CD4+ lymphocytes and
Effector T cells proliferation in response to OVA stimulation was
lls co-cultured with OVA323-339MAP group were four cycles, less than
epresent one of three independent experiments.
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costimulatory molecules of monocytes and DCs, thus
inhibiting the antigen-presenting function of these cells.
In addition, IL-10 could also regulate the humoral im-
mune response by promoting class-switch of immuno-
globulin and up-regulating IgG production [38,39]. In
the patients receiving PIT of bee venom or cat aller-
gen, the IL-10 levels significantly increased [13,40].
For this reason, we further observed the changes of
IL-10 levels in different groups. Our study showed that
OVA323-339MAP could increase the IL-10 level in
OVA challenge mice to a normal level, indicating that
inducing IL-10 secretion may be one of the functions
of OVA323-339MAP. Besides its tolerance-inducing capa-
bility, peptide immunotherapy-induced IL-10-dependent
immune tolerance correlates to inhibition of the “linkage
epitope” response [41]. In our study, subcutaneous injec-
tion of OVA323-339MAP could alleviate airway inflamma-
tion development and Th2 immune response in mice
challenged by the OVA protein, suggesting that OVA323-
339MAP therapy could inhibit in vivo immune response to
the entire OVA protein.
It is acknowledged that TGF-β1 could induce the con-
version of naïve CD4+CD25- T cells into CD4+CD25+ T
cells by up-regulating Foxp3 expression, and play an im-
portant role in enhancing the immunosuppressive capa-
city of CD4+CD25+ T cells [42,43]. Interestingly, the
levels of TGF-β1 in BALF of each group did not have
marked differences, while TGF-β1 transcription level in
the lung of OVA323-339MAP group was increased when
compared with the OVA group. The same phenomenon
had been observed in our previous study, suggesting that
membrane-bound TGF-β1 in CD4+CD25+ Treg cells
was elevated [25]. Some reports have demonstrated that
Treg cells could induce immune tolerance by cell-cell
contacting directly with membrane-bound TGF-β1 being
essential for this regulation, and it also could mitigate al-
lergic airway inflammation through a Notch1-mediated
mechanism [44,45]. It has been reported that PD-1
and CTLA-4 contribute to the suppressive activity of
allergen-specific regulatory cells, and are involved in the
peripheral tolerance. Several studies have confirmed that
PD-1 and its ligands (PD-L1 and PD-L2) as well as
CTLA-4 and ligands (B7-1 and B7-2) could drive the dif-
ferentiation of CD4+Foxp3+ T cells, down-regulate contact
hypersensitivity reaction, reduce airway hyperreactivity,
prevent eosinophil infiltration in the lungs, and prevent
IgE production [46-51]. Piconi et al. also found that during
allergen-specific immunotherapy, the expression of PD-L1
is increased compared with untreated control group [52],
which indirectly indicated that PD-1 played an important
role in inducing immune tolerance. In our study, we found
that the expression of PD-1 and CTLA-4 on Treg
cells in blood, mediastinal draining lymph nodes, andspleen did not alter noticeably between control and OVA
groups, whereas OVA323-339MAP intervention significantly
increased the expression of two molecules on the surface
of Treg cells. It also indicated that OVA323-339MAP
induced immune tolerance through cell-cell contacting
suppression is mediated by membrane-bound TGF-β1, as
well as PD-1 and CTLA-4.
As both cytokines and costimulatory molecules are
key factors for Treg cells activity, we investigated the
suppressive function of Treg cells. The function detec-
tion also showed that the inhibitory effect of Treg cell
from the OVA323-339MAP intervention mice on effector
T cells (Teff ) proliferation was superior to that of OVA
challenged mice. However, in clinical studies of PIT,
there is still controversy over the role of Treg cells. After
treatment with major T cell epitope of cat allergen Fel
d1, the Th2 immune response was inhibited in vivo, but
the inhibitory function of CD4+CD25+ Treg cells was
not significantly enhanced [24]. In another study on Fel
d1, after peptide treatment, a group of CD4+ T cells with
a regulatory effect significantly increased and could in-
hibit CD4- T cells function [23]. In addition, Wegman
et al.[16] found that MAPs treatment did not have a clear
effect on CD4+Foxp3+ cells in the mouse spleen and cen-
tral nervous system. However, our research showed that
OVA323-339MAP intervention could not only increase
the quantity of Treg cells, but also enhance their
function, accompanied by inversing Th1/Th2 balance,
regulating humoral immunity, and alleviating mouse
airway inflammation.
Conclusions
This study demonstrated that OVA323-339MAP, being dif-
ferent from OVA323-339 peptide, could inhibit the Th2
immune response and alleviate allergic airway inflamma-
tion in mice model and this function may be mediated
by Treg cells through direct and indirect mechanisms.
Methods
Experimental materials
In all experiments, 6 to 8 week-old female Balb/c mice
(purchased from the Shanghai SLAC Laboratory Animal
Co., Ltd.) were allocated randomly to either the experi-
mental group or the control group after 1-week adaptive
feeding under SPF conditions (n = 6 in each group). The
animal experiment protocols were approved by the Ethics
Committee of Ruijin Hospital Affiliated to Shanghai Jiao
Tong University School of Medicine. OVA323-339MAP oc-
tamers were kindly provided by Dr. Dave J Hinrichs at
Portland VA Medical Center. OVA323-339MAP is similar
to PLP139-151MAP as described by Wegman and Hinrichs
[16], The MAP core is almost the same and the only dif-
ference between them is the sequence of the leading pep-
tide. The amino acid sequence of the OVA323-339 peptide
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Glu-Ala-Gly-Arg.Preparation of the animal model and intervention
therapy
Airway inflammation mouse model was constructed and
the mice were interfered according to previous reports
[15,25,53]. In brief, each mouse involved with airway in-
flammation (OVA group) received an intraperitoneal in-
jection of 100 μg OVA (V grade, Sigma, USA) in 0.2 ml
Al(OH)3 adjuvant suspension on day 0 and day 14, re-
spectively. Following the OVA injection on day 14, the
mice were immediately intranasal challenged with
100 μg of OVA in 50 μl saline after anaesthetization via
inhalation of isoflurane. The same treatment was con-
ducted from day 32 to day 39, respectively. In the con-
trol group, mice received the same volume of Al(OH)3
to sensitize and saline to challenge. The intervention
therapy was started on day 27 and repeated on day 30.
In OVA323-339 group, 200 μg of OVA323-339 peptide
monomers (Anaspec, USA) in 200 μl saline was injected
subcutaneously into the back of mice. In the OVA323-
339MAP group, a series concentration of OVA323-
339MAP octamers (57.2, 114.4, 171.8 and 228.8 μg of
OVA323-339MAP equals to 50, 100, 150 and 200 μg of
OVA323-339 peptides, respectively) was injected in the
same way. The percentage of the lysine core matrix in
total mass was about 12.6% [16]. The concentration
series of OVA323-339MAP octamers were administrated
to evaluate the dose-effects of OVA323-339MAP in airway
inflammation mice. For comparison, on the same day of
treatment, equivalent volume of saline instead of the
OVA323-339 peptide monomers or OVA323-339MAP octa-
mers was subcutaneously injected in the control and
OVA groups.Tissue harvest
Twenty-four hour after the final challenge (day 40), all
mice were anaesthetized with isoflurane and sacrificed
after collecting blood via ophthalmic vein. For each
mouse, the trachea was exposed by blunt dissection.
Pre-cooled saline (0.4 ml) was slowly injected into the
trachea using a 22-gauge i.v. catheter for 3 times, the
BALF was collected. This procedure recovered 80 to
90% of the infused fluid.
After collecting BALF, mediastinal lymph nodes,
spleens, and lungs were collected. The right inferior lung
was fixed in 10% neutral formalin for 48 hours, embed-
ded in paraffin, and sectioned (4 μm) for hematoxylin-
eosin (HE) staining to observe airway inflammation
under the microscope (Olympus AX70, Japan). The left
lung was also removed and homogenized for RNA
extraction.Cell counts in BALF and analysis of peribronchial
inflammation
The collected BALF was centrifuged at 453 g at 4°C for
5 minutes. The supernatant was then stored at -80°C be-
fore further study. The cell pellet was resuspended in
500 μl saline and counted using a blood cell counting
plate. A small amount of the cell suspension was fixed
in 95% ethanol for 30 minutes for routine HE staining.
A total of 200 cells were randomly selected to calculate
EOS/NEU/MAC/LYM and their proportion under the
microscope (Olympus AX70, Japan). Different cell
counts were calculated by the following equation:
Total number ¼ number of target cell under the microscope
200
 
 total cell count
The severity of peribronchial inflammation was graded
semiquantitatively according to the published reference
[54] for the following features: 0: normal; 1: few cells; 2:
a ring of inflammatory cells, 1 cell layer deep; 3: a ring
of inflammatory cells, 2–4 cells deep; 4: a ring of inflam-
matory cells of 4 cells deep.
Cell culture
The single cell suspensions from the mediastinal lymph
nodes and spleens were prepared under sterile con-
ditions. Then RPMI-1640 complete culture medium
(containing 10% fetal bovine serum, 1% penicillin/
streptomycin, 0.1% 2-mercaptoethanol, Gibco, USA) was
added to adjust cell concentration to 5 × 106/ml and
these cells were seeded into a 24-well cell culture plate
(Corning, USA). The cells were then stimulated with
1 mg/ml OVA and incubated in the CO2 incubator with
5% CO2 and 95% humidity at 37°C. Five days later,
all wells were replaced with 1 ml fresh RPMI-1640 com-
plete culture medium without OVA, and cultivated over-
night under the same culture condition. Six hours before
cells collection, 50 ng/ml phorbol myristoyl acetate
(PMA, Sigma, USA), 1 μg/ml ionomycin (Sigma, USA)
and 1:1000 Brefeldin A (BFA, eBioscience, USA) were
added into each well to stimulate the cytokines secre-
tion. The primary culture supernatant was obtained for
cytokines detection and the cells were collected and
rinsed in PBS for FCM analysis.
ELISA
For the detection of OVA-sIgE, a 96-well ELISA plate
(Corning, USA) was coated with 100 μl coating buffer
(0.1 mol/L carbonate buffer, pH 9.5) containing OVA
(10 μg/ml), and then sealed and stored at 4°C overnight.
The plate was then washed three times with Phosphate
Buffered Saline (PBS) containing 0.05% Tween20 (PBS/T),
blocked with 200 μl blocking buffer (PBS containing 10%
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100 μl of each serum sample (diluted at 1:100) or mouse
OVA sIgE standards (Serotec, UK) were added in the
well. The standard was diluted into a final concentra-
tion series of 10000, 5000, 2500, 1250, 625, 312.5, 156.3
and 19.5 ng/ml, respectively. The plate was incubated at
37°C for 2 hours. After rinsing with PBS, 100 μl of horse-
radish peroxidase (HRP)-goat anti-mouse IgE antibody
(Serotec, UK, 1:5000) were added into each well, and in-
cubated at 37°C for additional 2 hours and rinsed for
detection.
For the detection of OVA-sIgG, a 96-well ELISA plate
was coated with 100 μl of coating buffer containing
rabbit anti-mouse IgG (H + L) (SouthernBiotech, USA,
1:8000) for each standard curve well and 100 μl coating
buffer containing OVA (1 μg/ml) for each sample well.
The plate was incubated at 4°C overnight, washed with
PBS/T three times, and then blocked for 2 hours at
room temperature. After rinsing, 100 μl mouse IgG1
standards (Southern Biotech, USA) of the dilution con-
centrations 1000, 200, 40, 8, 1.6, 0.32 and 0.16 ng/ml
were added to the standard curve wells and 100 μl
serum sample (1:500) were added into the OVA coated
wells. The plate was incubated at room temperature for 2
hours and rinsed with PBS/T. Finally, 100 μl of HRP-goat
anti-mouse IgG1 antibody (1:32000, SouthernBioetch,
USA) were added and incubated at room temperature for
2 hours and rinsed for analysis.
For detection, 100 μl of tetramethyl benzidine dihy-
drochloride (TMB) chromogenic reagent was added to
each well, and the plate was incubated at room tempe-
rature for 15 minutes before 100 μl H2SO4 (1 mol/L)
was added to terminate the reactions. The absorbance
was determined at 450 nm wavelength and the concen-
tration of OVA-sIgE or OVA-sIgG of each sample was
calculated based on the standard curve.
The levels of IL-4, IFN-γ, IL-5, IL-13, IL-10, and
TGF-β1 in BALF or cell culture supernatant were deter-
mined using ELISA kits according to the manufacturer’s
instructions (Biolegend, USA or eBioscience, USA).
Real-time PCR
After collecting BALF, the mice left lung was remo-
ved and homogenized, total RNA was extracted by
Trizol (Invitrogen Life Technologies). cDNA samples
were obtained by PrimeScript reverse transcriptase
(Takara, Japan). Real-time PCR was performed using
an ABI Prism 7900HT (Applied Biosysterms, Foster
Ctiy, CA) according to the manufacturer’s instructions.
Primer sequences specific for β-actin is forward primer
5’-CTA AGG CCA ACC GTG AAA AG-3’ and reverse
primer 5’-AGC CTG GAT GGC TAC GTA CAT-3’.
Primer sequences specific for IL-10 is forward primer
5’-AGA AGC ATG GCC CAG AAA TCA-3’ and reverseprimer 5’-GGC CTT GTA GAC ACC TTG GT-3’.
Primer sequences specific for TGF-β1 is forward primer
5’-ATC CTG TCC AAA CTA AGG CTC G-3’ and reverse
primer 5’-ACC TCT TTA GCA TAG TAG TCC GC-3’.
Primer sequences specific for Foxp3 is forward primer
5’-CCC AGG AAA GAC AGC AAC CTT-3’ and reverse
primer 5’-TTC TCC AAC CAG GCC ACT TG-3’. All pri-
mers were designed and synthesized by Invitrogen Cor-
poration. Reaction conditions were 2 minutes at 50°C,
10 minutes at 95°C, followed by 40 cycles of 95°C for 15
seconds and 60°C for 1 minute, finally, 50°C for 15
seconds, 60°C for 15 seconds and 95°C for 10 minutes.Flow cytometry
One hundred microlitre heparinized peripheral blood
were obtained and red blood cells were lysed to pre-
pare the single cell suspension. All cultured cells
from peripheral blood, mediastinal lymph nodes or
spleen were harvested, the surface staining antibodies
were FITC-anti-CD4, APC-anti-CD25, PE-anti-PD-1 or
PECY-7-anti-CTLA-4 and the intracellular staining anti-
bodies were PE-anti-IL-4, APC-anti-IFN-γ, PE-anti-Foxp3
or PECY-7-anti-Foxp3, together with isotype control stai-
ning. Meanwhile, after staining, the cells were washed
with PBS and fixed in 1% paraformaldehyde to count Th1,
Th2 and CD4+CD25+Foxp3+ Treg cells, as well as the
expression of PD-1 and CTLA-4 on the surface of Treg
cells. All antibodies were purchased from eBioscience
Company and procedures were carried out according to
the manufacturer’s instructions.
Immunomagnetic beads (Miltenyibiotec, USA) were
used to screen out spleenic CD4+CD25+ T cells from
mice in each group, as well as CD11c+ cells from mice
in the control group, according to the manufacturer’s
instructions. CD4+CD25- T cells in the control group mice
were collected as Teff, which were marked with carboxy-
fluorescein succinimidyl ester (CFSE; eBioscience, USA).
CD11c+ cells (2× 104) and CD4+CD25+ T cells (1× 105),
as well as CFSE-Teff (1× 105), were seeded into 96-well
round bottom plates (Corning, USA), co-cultured with
1 mg/ml OVA in the incubator at 37°C, with 5% CO2 and
95% humidity. After 5 days of cultivation, cells were col-
lected and stained with PE-anti-CD4, rinsed in PBS, and
fixed in 1% paraformaldehyde.
All stained cells were detected using the FACScan Flow
Analyzer and data were analyzed using FACS express v
3.0 software.Statistical analysis
Data were presented as mean ± standard deviation and
analyzed using SPSS16.0 software. Statistical comparisons
were made by One-Way ANOVA analysis in Figures 2, 3,
4 and 5.
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